00:06 , Jan 23, 2019 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models A 3-D human tissue model that mimics beating adult myocardium could help assess the effects of heart disease therapies on myocardial contractility. Generation and use of the biomimetic model involves five steps:...
01:11 , Jun 29, 2018 |  BC Innovations  |  Tools & Techniques

QT replacement plan

FDA has completed validation of a preclinical assay system that could replace clinical QT testing, a move it hopes will lower development costs and reduce false alarms of arrhythmia risk. The question for drug developers...
07:00 , Oct 1, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Potassium channel Kv10.2 (KCNH5; EAG2)

Cancer INDICATION: Brain cancer; cancer Mouse and patient sample studies suggest inhibiting KCNH5 could help treat metastatic medulloblastoma. In eight out of 10 patients with group 3 subtype medulloblastoma, levels of KCNH5 were higher in...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

Vanoxerine: Phase III started

Laguna began the double-blind, placebo-controlled, international Phase III RESTORE SR trial to evaluate a single dose of 400 mg oral vanoxerine in about 600 patients. Laguna Pharmaceuticals Inc. , La Jolla, Calif.   Product: Vanoxerine...
08:00 , Feb 23, 2015 |  BioCentury  |  Finance

An acute arrhythmia alternative

Laguna Pharmaceuticals Inc. plans to use a $30 million series B round to conduct a confirmatory Phase III trial of vanoxerine for acute treatment of atrial fibrillation and atrial flutter. The company is initially targeting...
01:37 , Feb 18, 2015 |  BC Extra  |  Financial News

Laguna raises $30M in B round

Laguna Pharmaceuticals Inc. (La Jolla, Calif.) raised $30 million in a series B round led by new investors Versant Ventures and Frazier Healthcare. New investor BioMed Ventures and existing investor Sante Ventures also participated. Formerly...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

Vanoxerine: Phase IIb data

The double-blind, Israeli and Russian Phase IIb COR-ART trial in 104 patients with symptomatic AF or flutter of recent onset showed that single oral doses of GBR-12909 reduced time to conversion to normal sinus rhythm...
07:00 , Aug 8, 2013 |  BC Innovations  |  Tools & Techniques

A new wave of arrhythmia assays

Cardiotoxicity testing has plagued drug developers for years as the principal preclinical test, the hERG assay, and the primary clinical marker, prolonged QT, are relatively poor predictors of proarrhythmic potential. Now, information about the different...
07:00 , Aug 5, 2013 |  BioCentury  |  Regulation

Rushing to abandon tQT

FDA 's Norman Stockbridge wants to abandon thorough QT studies by 2015, replacing them with a preclinical assay suite better able to detect proarrhythmia side effects than existing assays. However, it remains unclear whether two...
07:00 , Oct 18, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Arrhythmia Potassium channel Kv11.1 (KCNH2; hERG) High throughput screening and rabbit studies identified a modulator of ERG activity that could help prevent drug-induced arrhythmias....